Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: A comprehensive cross-sectional investigation

Prostate Cancer and Prostatic Diseases

Volumn 12, Issue 2, 2009, Pages 198-203

  Galvao D A ^a   Taaffe, D R ^b   Spry, N ^c,d   Joseph, D ^c,d   Turner, D ^a   Newton, R U ^a  

^a EDITH COWAN UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; GONADORELIN ANTAGONIST;

AGED; ANTIANDROGEN THERAPY; ARTICLE; BODY COMPOSITION; BODY DISTRIBUTION; BODY FAT; BONE DENSITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DOSE RESPONSE; DUAL ENERGY X RAY ABSORPTIOMETRY; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE EXERCISE; MUSCLE FUNCTION; MUSCLE STRENGTH; MUSCLE WEAKNESS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; TERTIARY HEALTH CARE;

ABSORPTIOMETRY, PHOTON; AGED; ANDROGEN ANTAGONISTS; BONE DENSITY; CROSS-SECTIONAL STUDIES; EXERCISE THERAPY; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MUSCLE STRENGTH; MUSCLE WEAKNESS; MUSCLE, SKELETAL; PHYSICAL ENDURANCE; PROSTATIC NEOPLASMS;

EID: 67349125430     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2008.51     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003; 95: 981-989.
3. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-4456.
4. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007; 99: 1516-1524.
5. Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006; 175: 136-139; discussion 139.
6. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91 1305-1308.
7. Galvaão DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int 2008; 102: 44-47.
8. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87 599-603.
9. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90: 6410-6417.
10. Rosenberg IH. Sarcopenia: Origins and clinical relevance. J Nutr 1997; 127: 990S-991S.
11. Galvaão DA, Taaffe DR, Spry N, Newton RU. Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer. Prostate Cancer Prostatic Dis 2007; 10 340-346.
12. Yancik R, Ganz PA, Varricchio CG, Conley B. Perspectives on comorbidity and cancer in older patients: Approaches to expand the knowledge base. J Clin Oncol 2001; 19: 1147-1151.
13. Taaffe DR, Duret C, Wheeler S, Marcus R. Once-weekly resistance exercise improves muscle strength and neuromuscular performance in older adults. J Am Geriatr Soc 1999; 47: 1208-1214.
14. Galvão DA, Taaffe DR. Resistance exercise dosage in older adults: single- versus multiset effects on physical performance and body composition. J Am Geriatr Soc 2005; 53: 2090-2097.
15. Fiatarone MA, Marks EC, Ryan ND, Meredith CN, Lipsitz LA, Evans WJ. High-intensity strength training in nonagenarians. Effects on skeletal muscle. JAMA 1990; 263: 3029-3034.
16. Taaffe DR, Simonsick EM, Visser M, Volpato S, Nevitt MC, Cauley JA et al. Lower extremity physical performance and hip bone mineral density in elderly black and white men and women: Cross-sectional associations in the Health ABC Study. J Gerontol A Biol Sci Med Sci 2003; 58 M934-M942.
17. Simonsick EM, Fan E, Fleg JL. Estimating cardiorespiratory fitness in well-functioning older adults: Treadmill validation of the long distance corridor walk. J Am Geriatr Soc 2006; 54: 127-132.
18. Newman AB, Simonsick EM, Naydeck BL, Boudreau RM, Kritchevsky SB, Nevitt MC et al. Association of long-distance corridor walk performance with mortality, cardiovascular disease, mobility limitation, and disability. JAMA 2006; 295: 2018-2026.
19. Simonsick EM, Montgomery PS, Newman AB, Bauer DC, Harris T. Measuring fitness in healthy older adults: The Health ABC Long Distance Corridor Walk. J Am Geriatr Soc 2001; 49: 1544-1548.
20. Taaffe DR, Lewis B, Marcus R. Quantifying the effect of hand preference on upper limb bone mineral and soft tissue composition in young and elderly women by dual-energy X-ray absorptiometry. Clin Physiol 1994; 14: 393-404.
21. Heymsfield SB, Smith R, Aulet M, Bensen B, Lichtman S, Wang J et al Appendicular skeletal muscle mass: Measurement by dual-photon absorptiometry. Am J Clin Nutr 1990; 52: 214-218.
22. Clay CA, Perera S, Wagner JM, Miller ME, Nelson JB, Greenspan SL. Physical function in men with prostate cancer on androgen deprivation therapy. Phys Ther 2007; 87: 1325-1333.
23. Levy ME, Perera S, van Londen GJ, Nelson JB, Clay CA, Greenspan SL. Physical function changes in prostate cancer patients on androgen deprivation therapy: A 2-year prospective study. Urology 2008; 71: 735-739.
24. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002; 346: 793-801.
25. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007; 110: 1493-1500.
26. D'Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS et al Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007; 25: 2420-2425.
27. Basaria S, Lieb II J, Tang AM, DeWeese T, Carducci M, Eisenberger M et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002; 56: 779-786.
28. Smith MR. Osteoporosis during androgen deprivation therapy for prostate cancer. Urology 2002; 60: 79-85.
29. Lee H, McGovern K, Finkelstein JS, Smith MR. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 2005; 104: 1633-1637.
30. Wolfson L, Judge J, Whipple R, King M. Strength is a major factor in balance, gait, and the occurrence of falls. J Gerontol A Biol Sci Med Sci 1995; 50 (Spec No): 64-67.
31. Pande I, Scott DL, O'Neill TW, Pritchard C, Woolf AD, Davis MJ. Quality of life, morbidity, and mortality after low trauma hip fracture in men. Ann Rheum Dis 2006; 65: 87-92.
32. Galvão DA, Nosaka K, Taaffe DR, Peake J, Spry N, Suzuki K et al Endocrine and immune responses to resistance training in prostate cancer patients. Prostate Cancer Prostatic Dis 2008; 11: 160-165.
33. Galvão DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR et al. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc 2006; 38: 2045-2052.
34. Galvão DA, Newton RU, Taaffe DR, Spry N. Can exercise ameliorate the increased risk of cardiovascular disease and diabetes associated with ADT? Nat Clin Pract Urol 2008; 5: 306-307.